Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • breezerwave breezerwave Feb 11, 2013 9:33 PM Flag

    Phase 2 study actively recruiting - Cabozantinib for Advanced Urothelial Cancer

    "Background:

    - Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It has not been approved for cancer treatment. However, studies have shown that prostate and ovarian tumors respond to it. Researchers want see if cabozantinib can be a safe and effective treatment for urothelial cancer."

    See clinical trials in progress.

    Sentiment: Strong Buy

 
EXEL
10.96+0.05(+0.46%)Aug 26 4:00 PMEDT